clinafloxacin

clinafloxacin

Antibiotics A broad-spectrum–gram-negative bacilli, staphylococci fluoroquinolone antibiotic with ↑ activity against streptococci and anaerobes; it is also active against PCP and toxoplasmosis Adverse effects Diarrhea due to Clostridium difficile overgrowth. See Fluoroquinolone.
References in periodicals archive ?
In vitro activity and rodent efficacy of clinafloxacin for bovine and swine respiratory disease.
In United States, Gatifloxacin was voluntarily withdrawn from the market by the manufacturer in 2006 [1], just as temafloxacin and clinafloxacin were withdrawn in the 1990s, due to numerous adverse drug events, including hypoglycaemia [2].
Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones.
In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.
Efficiacy of moxifloxacin, trovafloxacin, clinafloxacin, and levofloxacin against intracellular Legionella pneumophila.
In a prospective multicenter trial, clinafloxacin was effective in 87% of 53 patients with native valve infection (NVE), and 69% of 13 patients with prosthetic valve endocarditis (PVE).
Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.
Clinafloxacin, gemifloxacin, and sitfloxacin also have expanded spectra of activity against gram-positive and gram-negative bacteria.
Clinafloxacin, a new generation quinolone antibiotic for the hospital treatment of serious, life-threatening diseases.
0 [micro]g/mL; grepafloxacin, 32 [micro]g/mL; clinafloxacin, 2.